共查询到16条相似文献,搜索用时 406 毫秒
1.
2.
用转染EBV DNA Bam HI K片段后稳定表达EBNA-1的K_4细胞作为靶细胞,检测50份鼻咽癌病人和38份健康对照者血清中的IgG/EBNA-1抗体;阳性率分别为100%和92%。前者的平均几何滴度为89.4,后者为18.3,前者约为后者的5倍。同一批被检血清经SPA吸收去除IgG竞争性抑制后,鼻咽癌病人的IgA/EBNA-1抗体阳性率达78%(GMT 20.9),健康人的IgA/EBNA-1抗体阳性率仅5.3%,效价亦很低(GMT 5.2)。表明IgA/EBNA-1抗体对鼻咽癌是比较特异的,可考虑作为鼻咽癌血清学诊断的指标之一。 相似文献
3.
应用测定Epstein-Barr病毒(EB病毒)IgA/EA抗体的改进方法(见病毒学报,2:372,1986).将待检血清用与抗人IgG血清或葡萄球菌菌体蛋白(SPA)吸附,除去了竞争性IgG类抗体,增加了血清中IgA抗体与抗原相结合的机率,从而提高了免疫酶法的敏感性和鼻咽癌的检出率。用此法我们检查了来本实验室检查EB病毒相关抗体的2045人,大部份是进行体格检查、无自觉症状的健康人,其查出IgA/EA抗体阳性者42人,进一步做病理检查证实27人患鼻咽癌,其中属临床Ⅰ期者10人,Ⅱ期10人,Ⅲ期6人, 相似文献
4.
用3.5%PEG(MW6000)预先处理被检血清以除掉免疫复合物及干扰抗原之后,用新建立的ELISA方法测定血清中Epstein-Barr病毒早期抗原特异性抗体的抗独特型(Anti-Id)抗体。67例鼻咽癌患者中,80%IgA类的Anti-Id抗体阳性(P/N值≥2.1),而56例正常人群除1例阳性外,其余均阴性。测定46例鼻咽癌患者血清EA/IgA滴度与Anti-Id的关系表明,Anti-Id抗体P/N值与IgA/EA滴度呈负相关(r=-0.6,P<0.001)。12例鼻咽癌病人血清中EA抗体的IgG类Anti-Id抗体则与正常人无显著差别。 相似文献
5.
6.
7.
建立了一种检测脊髓灰质炎(简称脊灰)IgA抗体的捕捉法ELISA(Aac-ELISA)。方法敏感,快速,特异,用于检测144份脊灰可疑病人的血清,IgA抗体检出率为77.8%(112/144).而这些血清的IgM抗体检出率为65.2%(94/144)。如同时检测IgM和IgA抗体,则阳性率可达91.7%(132/144)。麻痹后1~3天内IgA的检出率为76.5%(13/17),4~7天内为95%(19/20)。最长检出IgA的一例可疑病人,其血清收集于病后第59天。本方法在一部分16天后可疑病人IgM阴性血清中查出IgA阳性,故可以作为查IgM抗体诊断方法的补充,尤其适用于诊断感染后未能及时收到血清标本,IgM已经转阴而IgA抗体仍为阳性的病人。 相似文献
8.
9.
10.
EB病毒膜抗原与系统性红斑狼疮相关性的实验研究 总被引:1,自引:0,他引:1
目的:探讨EB病毒膜抗原(MA)的表达与系统性红斑狼疮的关系.方法:用直接免疫荧光抗体法(DFA)检测MA在转基因小鼠体内的表达,用间接免疫荧光法(IFA)和免疫印迹法(IBT)分别检测血清中的抗核抗体(ANA)和抗ENA抗体,用Bradford法检测小鼠24h尿蛋白浓度.常规病理HE染色观察小鼠的肾脏病理改变,冰冻切片免疫荧光检测肾脏是否有免疫复合物沉积.结果:表达MA的转基因小鼠组,有8只小鼠ANA阳性,5只小鼠抗ENA抗体阳性,24h尿蛋白浓度平均值为4153.8 g/ml,小鼠肾脏存在多种病理改变及大量免疫复合物在肾小球沉积.对照组小鼠ANA、抗ENA抗体均为阴性,24h尿蛋白浓度平均值为382.7g/ml,肾脏未见病理改变.结论:EB病毒MA的表达可能引发SLE. 相似文献
11.
近年来,常用未经丙酮固定的、由丁酸和巴豆油激活的B95-8细胞或P3HR-1细胞为靶细胞,检测人血清中EB病毒IgA/MA抗体以早期诊断鼻咽癌,效果良好。但由于B95-8细胞含有多种EB病毒抗原,不能用丙酮固定,需多次离心沉淀,在浮悬状态下检测,技术比较复杂。 相似文献
12.
13.
14.
15.
将pUCB质粒表达的P83蛋白应用于免疫印迹法(IB)和ELISA中,检测了85例鼻咽癌(NPC)患者和100例健康人血清,同时与免疫酶法(IE)作比较。结果表明,免疫印迹法对NPC患者血清阳性检出率为94%;ELISA法阳性检出率为88%;而IE法阳性率为64%。三种方法检测健康人血清出现低水平IgA/EA抗体的阳性率分别为4%、3%及2%。用IE法检测IgA/EA抗体为阴性的NPC患者血清,用IB法检测的阳性率达87%,ELISA法阳性检出率为77%。IB法与ELISA法之间具有较好的正相关(r=0.67,P<0.01)。 相似文献
16.
Serological follow-up studies for up to 4 years on the levels of IgG antibody to EBV-determined nuclear antigen (EBNA) were carried out on 36 patients with nasopharyngeal carcinoma (NPC). The serum levels of IgA antibody specific to EBV capsid antigen (VCA) were also measured in some of the patients. The titers of EBNA antibody were measured by enzyme-linked immunosorbent assay (ELISA) and those of IgA antibody to VCA were measured by the indirect immunofluorescence method. The EBNA antibody titers in most sera from the patients before radiation therapy were found to be at least 4 times the mean values in the sera of healthy control adults. Within 2 to 8 months after completion of therapy by 4-MV liniac X-ray irradiation with total doses of 60 to 80 Gy, the titers of EBNA antibody in the sera of 6 patients had returned to normal levels, and low levels of EBNA antibody were maintained for a long time after therapy. These serological data were associated with a good clinical prognosis without recurrence or metastases. But in 6 patients, the patterns of change in the EBNA antibody levels were different: the levels remained high after therapy or first decreased to the normal level and then rose to at least 4 times this level. These 6 patients showed recurrence or metastases. The patterns of change in the EBNA antibody levels were well correlated with those of change in the levels of IgA antibody specific to VCA.(ABSTRACT TRUNCATED AT 250 WORDS) 相似文献